YMDD motif mutants in hepatitis B virus polymerase during lamivudine therapy

Korean Journal of Genetics

Volumn 24, Issue 2, 2002, Pages 219-226

  Han, Jin Hee ^a,b   Hwang, Seong Gyu ^a   Chung, Ki Wha ^b   Oh, Seong Wook ^a   Hong, Sung Pyo ^a   Park, Pil Won ^a   Rim, Kyu Sung ^a   Oh, Doyeun ^a   Kim, Nam Keun ^a  

^a CHA University   (South Korea)

^b Kongju National University   (South Korea)

Author keywords

Drug resistance; HBV; Lamivudine; Mutation; YMDD motif

Indexed keywords

ENZYME; LAMIVUDINE; POLYMERASE; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL MEDICINE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MUTANT; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TIME;

HEPATITIS B VIRUS;

EID: 0038722939     PISSN: 02545934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ahmed SNS, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C and Zoulim F (2000) Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32: 1078-1088.
2. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER and Brown NA (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22.
3. Chang CN, Dkalski V, Zhou JH and Cheng YC (1992) Biochemical pharmacology of (+)- and (-)-2′, 3′-dedeoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 31: 22414-22420.
4. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K and Kumada H (1998) Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27: 1711-1716.
5. Cho SW, Hahm KB and Kim JH (2000) Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 32: 1163-1169.
6. Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG and Arnold E (2001) Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FFC). J. Virol. 75: 4771-4779.
7. Doong SL, Tsai CH, Schinazi RF, Liotta DC and Cheng YC (1991) Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dedeoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 19: 8495-8499.
8. Ganem D and Varmus HE (1987) The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem. 56: 651-693.
9. Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, Villeneuve, JP, Fischer KP and Tyrrel DL (2000) Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J. Hepatol. 33: 469-475.
10. Jarvis B and Faulds D (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58: 101-141.
11. Kobayashi M and Koike K (1984) Complete nucleotide sequence of hepatitis virus DNA of subtype adr and its conserved gene organization. Gene 30: 227-232.
12. Kwak DS, Kim JY, Lee YI and Jung GH (1996) Expression and purification of human hepatitis B virus polymerase with a dual affinity Tag. Korean J. Genetics 18(2): 131-138.
13. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Wu PC and Dent JC (1998) A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339: 61-63.
14. Lai CL, Chien RN, Leung NWY, Deslauriers M, Barnard J, Sanathanan L and Gray DF (1997) Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters (Abstracts). Hepatology 26: 259A.
15. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ and Hoofnagle J (2000) Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32: 828-834.
16. Lee SW and Lee SG (1986) The cytogenetic effects of herpes simplex virus on cultured human leukocytes. Korean J. Genetics 8(1): 23-33.
17. Mason WS, Cullen J, Moraleda G, Saputelli J, Aldrich CE, Miller DS and Tennant B (1998) Lamivudine therapy of WHV-infected woodchucks. Virology 245: 18-32.
18. Ogata N, Fujii K, Takigawa S, Nomoto M, Ichida T and Asakura H (1999) Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J. Med. Virol. 59: 270-276.
19. Ononita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ and Omata M (1999) YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29: 939-945.
20. Paik YH, Han KH, Chung HY, Chon CY and Moon YM (1999) Emergence of YMDD motif mutant hepatitis B virus during short-term lamivudine therapy. Korean J. Hepatol. 5: 173-183.
21. Paik YH, Chung HY, Ryu WS, Lee KS, Lee JS, Kim JH, Lee CK, Chon CY, Moon YM and Han KH (2001) Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. J. Hepatol. 35(1): 92-98.
22. Pichoud C, Seigneres B, Wang Z, Trepo C and Zoulim F (1999) Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29: 230-237.
23. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL and Schinazi RF (2001) Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33: 751-757.
24. Stuyver L, Van GC, Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G and Rossau R (2000) Line probe assay for monitoring drag resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 38: 702-707.
25. Suh DJ, Chung YH, Lee YS, Lee MH and Han KH (1999) Effect and safety of 12 week lamivudine therapy in patients with chronic hepatitis B. Korean J. Hepatol. 5: 89-96.
26. Summers J and Mason WS (1982) Replication of the genome of a hepatitis like virus by reverse transcription of an RNA intermediate. Cell 29: 403-415.
27. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L and Gray DF (1999) Efficacy of lamivudine in patients with hepatitis B e antigen negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29: 889-896.
28. Tiollais P, Pourcel C and Dejean A (1985) The hepatitis B virus. Nature 317: 489-495.
29. World Health Organization (1997) World Health Organization warns of growing "crisis of suffering." http://www.who.ch/whr/1997/presse. htm.